CD1d–invariant natural killer T cell receptor axis (CD1d–iNKT axis)

The CD1d–invariant natural killer T cell (iNKT) receptor axis is a unique immunological pathway involving the presentation of lipid antigens by the CD1d molecule to the semi-invariant T-cell receptor (TCR) of iNKT cells [1, 2]. CD1d is a non-polymorphic, MHC class I-like protein that specializes in binding glycolipids rather than peptides [3]. Upon recognition of these lipids, iNKT cells are rapidly activated, bridging innate and adaptive immunity by secreting large quantities of Th1, Th2, and Th17 cytokines [1, 4]. This axis is a significant therapeutic target in oncology, where agonists like alpha-galactosylceramide (α-GalCer) are used to induce potent anti-tumor responses through the trans-activation of natural killer (NK) cells and CD8+ T cells [5]. Beyond cancer, the axis is implicated in regulating autoimmune diseases, metabolic inflammation, and infectious diseases [2, 6]. Clinical development focuses on optimizing glycolipid ligands to bias the cytokine response toward a desired therapeutic outcome while avoiding iNKT cell exhaustion [4, 5]. The axis also serves as a target for vaccine adjuvants, enhancing the magnitude and quality of the adaptive immune response to co-administered antigens [6]. However, the potential for systemic cytokine release and the induction of long-term iNKT cell unresponsiveness remain key challenges in drug development [1, 5].

Other names

CD1d-iNKT axisCD1d-restricted iNKT cell activationCD1d-NKT cell interactionCD1d-iNKT cell receptor complex

Agonism of the iNKT TCR via CD1d-mediated presentation of glycolipid antigens, leading to rapid cytokine production and trans-activation of NK cells, dendritic cells, and B cells.